SITRA
24.10.2016 14:49:39 CEST | Business Wire | Press release
The world is in serious need of solutions concerning how to sustainably create growth and jobs. A pioneering event will offer those solutions in June 2017 in Helsinki, Finland. The agenda features the world’s best circular economy solutions based on the implementation of the UN’s Sustainable Development Goals. The event is organised by Sitra together with a large group of global institutions.
Sitra is inviting the future shapers of our well-being to celebrate Finland’s 100th year of independence at the World Circular Economy Forum 2017 in Helsinki. The event (5-6 June 2017) brings together 1,200 international business and NGO leaders, managers, urban experts and government officials.
The focus of the event is on genuinely sustainable and competitive solutions for the circular economy – on solutions that have been created in different parts of the world and in which business and the environment go hand in hand. The circular economy plays an important role in the realisation of the UN’s Sustainable Development Goals.
”We will also explain how Finland, as the first country in the world, is implementing its national roadmap of the circular economy – how the whole society is increasing its competitiveness and benefiting from moving to a new operational model for the economy, a model in which the growth of the economy and well-being are no longer based on the overconsumption of natural resources and fossil fuels”, says Mari Pantsar , the director resource-wise and carbon-neutral activities in Sitra.
The group of most recognized speakers presenting diverse solutions for the circular economy at the World Circular Economy Forum covers a large spectrum of the world’s top experts. Among the participants are Achim Steiner , the former head of the UN’s Environment Programme; Jyrki Katainen , EU Commissioner; Ashok Khosla , Founder and President of Development Alternatives and Co-chair of the UN’s International Resource Panel; Janez Potocnik , Co-chair of the UN’s International Resource Panel and Matti Lievonen , Managing director of Neste.
The organisers of the WCEF2017 are Sitra, the Nordic Council of Ministers, the Ministry of the Environment and the Ministry of Economic Affairs and Employment in cooperation with the following institutions: European Commission, European Environment Agency (EEA), International Institute for Sustainable Development (IISD), Koli Forum, United Nations Environment Programme (UNEP), World Business Council for Sustainable Development (WBCSD) and World Resources Forum (WRF).
Website of the event www.wcef2017.com
Sitra is a future fund that collaborates with partners from different sectors to research, trial and implement bold new ideas that shape the future. Our aim is a Finland that succeeds as a pioneer in sustainable well-being.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005743/en/
Contact:
Sitra
Hanna-Leena Ottelin, Specialist
hanna-leena.ottelin(at)sitra.fi
+358
(0)50 376 9499
or
Kari Herlevi, Senior Lead
kari.herlevi(at)sitra.fi
+358
(0)50 463 9397
or
Samuli Laita, Communications
samuli.laita(at)sitra.fi
+358
(0)40 536 8650
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom